Inventor · disambiguated record
Thomas R. Diraimondo
Also filed as: DIRAIMONDO THOMAS · DIRAIMONDO THOMAS R
7 granted patents·25 pending applications·12 citations·filing 2012–2025
78Inventor score
Top patents by PatentIndex Score
32 records- 0194US11512113B2Cleavable linker compositions and methodsJANUX THERAPEUTICS INC·Filed 2021·Granted Nov 29, 2022·7 cites·25 claims
- 0292US11548892B1Transglutaminase 2 (TG2) inhibitorsSITARI PHARMA INC·Filed 2022·Granted Jan 10, 2023·4 cites·6 claims
- 0388US12161724B2Compositions and methods related to tumor activated antibodies targeting EGFR and effector cell antigensJANUX THERAPEUTICS INC·Filed 2022·Granted Dec 10, 2024·1 cites·21 claims
- 0480US12433953B2Compositions and methods related to tumor activated antibodies targeting EGFR and effector cell antigensJANUX THERAPEUTICS INC·Filed 2024·Granted Oct 7, 2025·0 cites·31 claims
- 0578US2024376226A1Compositions and methods relating to tumor activated t cell engagersJANUX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0678US2025019403A1Cleavable linker compositions and methodsJANUX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0778US2025011324A1Transglutaminase 2 (tg2) inhibitorsSITARI PHARMA INC·Filed 2024·Application pending·0 cites
- 0872US2023348618A1Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigensJANUX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 0971US2023147782A1Cleavable linker compositions and methodsJANUX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1070US11555078B2Compositions and methods related to tumor activated antibodies targeting PSMA and effector cell antigensJANUX THERAPEUTICS INC·Filed 2021·Granted Jan 17, 2023·0 cites·26 claims
- 1164US12152026B2Transglutaminase 2 (TG2) inhibitorsSITARI PHARMA INC·Filed 2019·Granted Nov 26, 2024·0 cites·27 claims
- 1262US2023220105A1Tumor activated t cell engagers and methods of use thereofJANUX THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1362US2023220109A1Compositions and methods relating to tumor activated t cell engagersJANUX THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1461US2023357429A1Optimized antibodies targeting trop2 and uses thereofJANUX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1561US2023357447A1Tumor activated multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereofJANUX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1660US2025154278A1Optimized antibodies targeting trop2 and uses thereofJANUX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1760US2024059790A1Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigensJANUX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1858US2024254241A1Antibodies targeting egfr and cd3 and uses thereofJANUX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1956US2024034814A1Half-life extending compositions and methodsJANUX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2055US2024043536A1Peptide compositions and methods for anti-cd3 binding domainsJANUX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2155US2024034806A1Compositions and methods related to tumor activated antibodies targeting trop2 and effector cell antigensJANUX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2254US2023406955A1Antibodies targeting her2 and cd3 and uses thereofJANUX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2354US2021115106A1Modified t cell receptorsJANUX THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2454US2024092931A1Antibodies targeting trop2 and cd3 and uses thereofJANUX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2554US2024043565A1Antibodies targeting psma and cd3 and uses thereofJANUX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2654US2023406937A1Multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereofJANUX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2754US2020385440A1Modified bispecific t cell receptorsJANUX THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2851US2025250339A1Antibodies targeting egfr and cd3 and uses thereofJANUX THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2949US2025297017A1Compositions and uses of tumor activated antibodies targeting egfr and effector cell antigensJANUX THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3046US10010541B2Modulation of tissue transglutaminase activation in diseaseUNIV LELAND STANFORD JUNIOR·Filed 2015·Granted Jul 3, 2018·0 cites·12 claims
- 3139US2017266198A1Modulation of tissue transglutaminase activation in diseaseUNIV LELAND STANFORD JUNIOR·Filed 2017·Application pending·0 cites
- 3238US2014322278A1Modulation of Tissue Transglutaminase Activation in DiseaseDIRAIMONDO THOMAS·Filed 2012·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Thomas R. Diraimondo files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →